Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.

Blain JF, Bursavich MG, Freeman EA, Hrdlicka LA, Hodgdon HE, Chen T, Costa DE, Harrison BA, Kapadnis S, Murphy DA, Nolan S, Tu Z, Tang C, Burnett DA, Patzke H, Koenig G.

Alzheimers Res Ther. 2016 Aug 30;8:34. doi: 10.1186/s13195-016-0199-5.

2.

Loss of Aβ43 Production Caused by Presenilin-1 Mutations in the Knockin Mouse Brain.

Xia D, Kelleher RJ 3rd, Shen J.

Neuron. 2016 Apr 20;90(2):417-22. doi: 10.1016/j.neuron.2016.03.009.

3.

Effect of Presenilin Mutations on APP Cleavage; Insights into the Pathogenesis of FAD.

Li N, Liu K, Qiu Y, Ren Z, Dai R, Deng Y, Qing H.

Front Aging Neurosci. 2016 Mar 11;8:51. doi: 10.3389/fnagi.2016.00051. eCollection 2016.

4.

γ-Secretase Modulators and APH1 Isoforms Modulate γ-Secretase Cleavage but Not Position of ε-Cleavage of the Amyloid Precursor Protein (APP).

Lessard CB, Cottrell BA, Maruyama H, Suresh S, Golde TE, Koo EH.

PLoS One. 2015 Dec 17;10(12):e0144758. doi: 10.1371/journal.pone.0144758. eCollection 2015.

5.

Suppressor Mutations for Presenilin 1 Familial Alzheimer Disease Mutants Modulate γ-Secretase Activities.

Futai E, Osawa S, Cai T, Fujisawa T, Ishiura S, Tomita T.

J Biol Chem. 2016 Jan 1;291(1):435-46. doi: 10.1074/jbc.M114.629287. Epub 2015 Nov 11.

6.

Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment.

Brendel M, Jaworska A, Herms J, Trambauer J, Rötzer C, Gildehaus FJ, Carlsen J, Cumming P, Bylund J, Luebbers T, Bartenstein P, Steiner H, Haass C, Baumann K, Rominger A.

Mol Psychiatry. 2015 Oct;20(10):1179-87. doi: 10.1038/mp.2015.74. Epub 2015 Jun 9.

7.

Cleavage of amyloid precursor protein by an archaeal presenilin homologue PSH.

Dang S, Wu S, Wang J, Li H, Huang M, He W, Li YM, Wong CC, Shi Y.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3344-9. doi: 10.1073/pnas.1502150112. Epub 2015 Mar 2.

8.

Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers.

Liu Q, Waltz S, Woodruff G, Ouyang J, Israel MA, Herrera C, Sarsoza F, Tanzi RE, Koo EH, Ringman JM, Goldstein LS, Wagner SL, Yuan SH.

JAMA Neurol. 2014 Dec;71(12):1481-9. doi: 10.1001/jamaneurol.2014.2482.

9.

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780.

Toyn JH, Thompson LA, Lentz KA, Meredith JE Jr, Burton CR, Sankaranararyanan S, Guss V, Hall T, Iben LG, Krause CM, Krause R, Lin XA, Pierdomenico M, Polson C, Robertson AS, Denton RR, Grace JE, Morrison J, Raybon J, Zhuo X, Snow K, Padmanabha R, Agler M, Esposito K, Harden D, Prack M, Varma S, Wong V, Zhu Y, Zvyaga T, Gerritz S, Marcin LR, Higgins MA, Shi J, Wei C, Cantone JL, Drexler DM, Macor JE, Olson RE, Ahlijanian MK, Albright CF.

Int J Alzheimers Dis. 2014;2014:431858. doi: 10.1155/2014/431858. Epub 2014 Jul 8.

10.

Changed membrane integration and catalytic site conformation are two mechanisms behind the increased Aβ42/Aβ40 ratio by presenilin 1 familial Alzheimer-linked mutations.

Wanngren J, Lara P, Ojemalm K, Maioli S, Moradi N, Chen L, Tjernberg LO, Lundkvist J, Nilsson I, Karlström H.

FEBS Open Bio. 2014 Apr 24;4:393-406. doi: 10.1016/j.fob.2014.04.006. eCollection 2014.

11.

Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species.

Wagner SL, Zhang C, Cheng S, Nguyen P, Zhang X, Rynearson KD, Wang R, Li Y, Sisodia SS, Mobley WC, Tanzi RE.

Biochemistry. 2014 Feb 4;53(4):702-13. doi: 10.1021/bi401537v. Epub 2014 Jan 22.

12.

Development and mechanism of γ-secretase modulators for Alzheimer's disease.

Crump CJ, Johnson DS, Li YM.

Biochemistry. 2013 May 14;52(19):3197-216. doi: 10.1021/bi400377p. Epub 2013 May 2. Review.

13.

Aftins increase amyloid-β42, lower amyloid-β38, and do not alter amyloid-β40 extracellular production in vitro: toward a chemical model of Alzheimer's disease?

Hochard A, Oumata N, Bettayeb K, Gloulou O, Fant X, Durieu E, Buron N, Porceddu M, Borgne-Sanchez A, Galons H, Flajolet M, Meijer L.

J Alzheimers Dis. 2013;35(1):107-20. doi: 10.3233/JAD-121777.

14.
15.

First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.

Borgegard T, Juréus A, Olsson F, Rosqvist S, Sabirsh A, Rotticci D, Paulsen K, Klintenberg R, Yan H, Waldman M, Stromberg K, Nord J, Johansson J, Regner A, Parpal S, Malinowsky D, Radesater AC, Li T, Singh R, Eriksson H, Lundkvist J.

J Biol Chem. 2012 Apr 6;287(15):11810-9. doi: 10.1074/jbc.M111.305227. Epub 2012 Feb 13.

16.

Dissociation between the processivity and total activity of γ-secretase: implications for the mechanism of Alzheimer's disease-causing presenilin mutations.

Quintero-Monzon O, Martin MM, Fernandez MA, Cappello CA, Krzysiak AJ, Osenkowski P, Wolfe MS.

Biochemistry. 2011 Oct 25;50(42):9023-35. doi: 10.1021/bi2007146. Epub 2011 Sep 30.

17.

Novel γ-secretase enzyme modulators directly target presenilin protein.

Ebke A, Luebbers T, Fukumori A, Shirotani K, Haass C, Baumann K, Steiner H.

J Biol Chem. 2011 Oct 28;286(43):37181-6. doi: 10.1074/jbc.C111.276972. Epub 2011 Sep 6.

Supplemental Content

Support Center